Rutgers Cancer Institute Leader Named Executive Officer of Big Ten Cancer Research Consortium
Source Newsroom: Rutgers Cancer Institute of New Jersey
Rutgers Cancer Institute of New Jersey Leader Tapped for National Post
Dr. Susan Goodin named Executive Officer of Big Ten Cancer Research Consortium
Newswise — New Brunswick, N.J., May 30, 2014 – Susan Goodin, PharmD, executive director of statewide affairs at Rutgers Cancer Institute of New Jersey, has been appointed to serve as Executive Officer of the Big Ten Cancer Research Consortium (BTCRC).
The BTCRC, which fosters scientific collaboration between cancer centers at universities that are part of the Big Ten Conference, aims to develop unique nationwide clinical trial opportunities for patients. In this role, Dr. Goodin will work closely with the consortium’s administration and member institutions to carry out this mission that has an initial focus of developing cutting-edge treatments for genitourinary, gastrointestinal, thoracic and breast cancers.
An active researcher for more than 20 years, the Cranford resident has helped lead clinical research activity at the Cancer Institute of New Jersey, having served as an Associate Director of Clinical Trials and Therapeutics. She also has been a principal investigator on a number of translational trials. A professor of medicine at Rutgers Robert Wood Johnson Medical School, Goodin also has served as director of the Cancer Institute’s Division of Pharmaceutical Sciences.
“I am honored to have been selected to serve in this capacity for the Big Ten Cancer Research Consortium,” notes Goodin. “In an era when targeted cancer therapies are no longer a prediction, but a reality, these elite centers will incorporate their groundbreaking science into novel clinical trials. And by working collaboratively in a consortium environment, we will have the opportunity to elucidate these discoveries rapidly.”
Goodin is a founding member of the Hematology/Oncology Pharmacists Association, serves on the editorial board of Clinical Therapeutics and is a journal reviewer for the New England Journal of Medicine, Clinical Cancer Research and Clinical Therapeutics among others. She also has authored numerous scientific publications and has presented nationally on the topics of cancer treatment, chemoprevention and supportive care.
About Rutgers Cancer Institute of New Jersey
Rutgers Cancer Institute of New Jersey (www.cinj.org) is the state’s first and only National Cancer Institute-designated Comprehensive Cancer Center. As part of Rutgers, The State University of New Jersey, the Cancer Institute of New Jersey is dedicated to improving the detection, treatment and care of patients with cancer, and to serving as an education resource for cancer prevention. Physician-scientists at the Cancer Institute engage in translational research, transforming their laboratory discoveries into clinical practice, quite literally bringing research to life. To make a tax-deductible gift to support the Cancer Institute of New Jersey, call 732-235-8614 or visit www.cinj.org/giving. Follow us on Facebook at www.facebook.com/TheCINJ.
The Cancer Institute of New Jersey Network is comprised of hospitals throughout the state and provides the highest quality cancer care and rapid dissemination of important discoveries into the community. Flagship Hospital: Robert Wood Johnson University Hospital. System Partner: Meridian Health (Jersey Shore University Medical Center, Ocean Medical Center, Riverview Medical Center, Southern Ocean Medical Center, and Bayshore Community Hospital). Major Clinical Research Affiliate Hospitals: Carol G. Simon Cancer Center at Morristown Medical Center, Carol G. Simon Cancer Center at Overlook Medical Center, and Cooper University Hospital. Affiliate Hospitals: JFK Medical Center, Robert Wood Johnson University Hospital Hamilton (CINJ Hamilton), Shore Medical Center, Somerset Medical Center, The University Hospital and University Medical Center of Princeton at Plainsboro.